Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: A multicentre retrospective study of 22 cases

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 64-71

  Song, Seung Taek ^a   Kim, Jin Ju ^a   Lee, Seung ^a   Kim, Hyoun Ah ^b   Lee, Eun Young ^c   Shin, KiChul ^c   Lee, Joo Hyun ^d   Lee, Kwang Hoon ^e   Choi, Sang Tae ^f   Cha, Hoon Suk ^g   Yoo, Dae Hyun ^a  

^a Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Inje University   (South Korea)

^e Dongguk University Ilsan Hospital   (South Korea)

^f Chung Ang University College of Medicine   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adult onset Still's disease; Biological agents; Interleukin; Refractory; Tocilizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; FERRITIN; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADULT ONSET STILL DISEASE; AGED; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FOLLOW UP; HAIR LOSS; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; LEUKOPENIA; MULTICENTER STUDY; POLYARTHRITIS; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; MALE; MIDDLE AGED; SOUTH KOREA; STILL'S DISEASE, ADULT-ONSET; TIME FACTOR; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; STILL'S DISEASE, ADULT-ONSET; TIME FACTORS; TREATMENT OUTCOME;

EID: 85012852784     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. EFTHIMIOU P, PAIK PK, BIELORY L: Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006; 65: 564-72.
2. BALCI MA, PAMUK ON, PAMUK GE, UZUNDERE FK, DONMEZ S: Epidemiology and outcome of adult-onset Still's disease in Northwestern Thrace region in Turkey. Clin Exp Rheumatol 2015.
3. CABANE J, MICHON A, ZIZA JM et al.: Comparison of long term evolution of adult onset and juvenile onset Still's disease, both followed up for more than 10 years. Ann Rheum Dis 1990; 49: 283-5.
4. AYDINTUG AO, D'CRUZ D, CERVERA R, KHAMASHTA MA, HUGHES GR: Low dose methotrexate treatment in adult Still's disease. J Rheumatol 1992; 19: 431-5.
5. CURTIS JR, WESTFALL AO, ALLISON J et al.: Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55: 420-6.
6. HUSCHER D, THIELE K, GROMNICA-IHLE E et al.: Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119-24.
7. BOUMPAS DT, CHROUSOS GP, WILDER RL, CUPPS TR, BALOW JE: Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119: 1198-208.
8. EFTHIMIOU P, KONTZIAS A, WARD CM, OGDEN NS: Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 2007; 3: 328-35.
9. CHEN DY, LAN JL, LIN FJ, HSIEH TY: Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004; 31: 2189-98.
10. CANTARINI L, RIGANTE D: Adult-onset autoinflammatory disorders: a still debated entity? Clin Exp Rheumatol 2015; 33: 137-40.
11. De BENEDETTI F, MASSA M, PIGNATTI P, ALBANI S, NOVICK D, MARTINI A: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93: 2114-9.
12. De BENEDETTI F: Tocilizumab for systemic juvenile idiopathic arthritis. New Engl J Med 2013; 368: 1256-7.
13. FAUTREL B, SIBILIA J, MARIETTE X, COMBE B: Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005; 64: 262-6.
14. NORDSTROM D, KNIGHT A, LUUKKAINEN R et al.: Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol 2012; 39: 2008-11.
15. GIAMPIETRO C, RIDENE M, LEQUERRE T et al.: Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res 2013; 65: 822-6.
16. LEQUERRE T, QUARTIER P, ROSELLINI D et al.: Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemiconset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-8.
17. de BOYSSON H, FEVRIER J, NICOLLE A, AUZARY C, GEFFRAY L: Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence. Clin Rheumatol 2013; 32: 141-7.
18. PUECHAL X, DeBANDT M, BERTHELOT JM et al.: Tocilizumab in refractory adult Still's disease. Arthritis Care Res 2011; 63: 155-9.
19. ELKAYAM O, JIRIES N, DRANITZKI Z et al.: Tocilizumab in adult-onset Still's disease: the Israeli experience. J Rheumatol 2014; 41: 244-7.
20. CIPRIANI P, RUSCITTI P, CARUBBI F et al.: Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol 2014; 33: 49-55.
21. GERFAUD-VALENTIN M, MAUCORT-BOULCH D, HOT A et al.: Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine 2014; 93: 91-9.
22. LO GULLO A, CARUSO A, PIPITONE N, MACCHIONI P, PAZZOLA G, SALVARANI C: Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations. Joint Bone Spine 2014; 81: 376-7.
23. YAMAGUCHI M, OHTA A, TSUNEMATSU T et al.: Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 424-30.
24. RAU M, SCHILLER M, KRIENKE S, HEYDER P, LORENZ H, BLANK N: Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. J Rheumatol 2010; 37: 2369-76.
25. ORTIZ-SANJUAN F, BLANCO R, CALVO-RIO V et al.: Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheum (Hoboken, NJ) 2014; 66: 1659-65.
26. BAGNARI V, COLINA M, CIANCIO G, GOVONI M, TROTTA F: Adult-onset Still's disease. Rheumatology Int 2010; 30: 855-62.
27. HOSHINO T, OHTA A, YANG D et al.: Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 1998; 25: 396-8.
28. FUJII T, NOJIMA T, YASUOKA H et al.: Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford) 2001; 40: 1398-404.
29. KREMER JM, BLANCO R, BRZOSKO M et al.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
30. STRAND V, BURMESTER GR, OGALE S, DEVENPORT J, JOHN A, EMERY P: Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 2012; 51: 1860-9.
31. MAINI RN, TAYLOR PC, SZECHINSKI J et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.
32. YOKOTA S, IMAGAWA T, MORI M et al.: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
33. WOO P, WILKINSON N, PRIEUR AM et al.: Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 re ceptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7: R1281-8.
34. RINGOLD S, WEISS PF, BEUKELMAN T et al.: 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013; 65: 2499-512.
35. DeWITT EM, KIMURA Y, BEUKELMAN T et al.: Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 2012; 64: 1001-10.
36. De BENEDETTI F, BRUNNER HI, RUPERTO N et al.: Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. New Engl J Med 2012; 367: 2385-95.
37. van GESTEL AM, PREVOO ML, van HOF MA, van RIJSWIJK MH, van de PUTTE LB, van RIEL PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.